Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 232

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 232
---
 30 days after the completion of the Business Combination, except as described below.

See “ Description of ParentCo Capital Stock — Warrants — Public Warrants ” for a further description of the Warrant Amendment.

#### Regulatory Approvals
The Business Combination and the transactions contemplated by the Business Combination Agreement are not subject to any additional regulatory requirement or approval, except for filings required with the SEC pursuant to the reporting requirements applicable to Iris, and the requirements of the Securities Act and the Exchange Act, including the requirement to file the registration statement of which this proxy statement/ prospectus forms a part and to disseminate it to its stockholders.

### Background of the Business Combination
Iris (formerly known as Tribe Capital Growth Corp I) is a blank check company formed as a corporation in Delaware on November 5, 2020 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. For purposes of this section, “Tribe Capital Growth” refers to Iris prior to its management and name change that occurred on or about July 27, 2022, as described in the section titled “ Iris’s Management’s Discussion And Analysis Of Financial Condition And Results Of Operations — Overview” in this proxy statement/ prospectus .

The Business Combination with Liminatus is the result of an extensive search for a potential initial business combination, whereby Iris evaluated a large number of potential targets utilizing the investing, operating and transaction experience of Iris’s management team, advisory partners and the Iris Board. The terms of the Business Combination are the result of arm’s-length negotiations between representatives of Iris and representatives of Liminatus. The following is a brief discussion of the background of these negotiations, the Business Combination Agreement and related transactions.

Prior to the pricing of the IPO, neither Iris, nor any authorized person on its behalf, initiated any substantive discussions, formal or otherwise, with respect to a business combination involving Liminatus.

On March 9, 2021, Tribe Capital Growth priced its initial public offering of 27,600,000 units, including 3,600,000 units issued pursuant to the exercise of the underwriters’ over-allotment option in full at an offering

<div align='center'>107</div>

TABLE OF CONTENTS

price of $10.00 per unit. Each unit consists of one share of Class A common stock of Tribe Capital Growth at par value $0.0001 per share and one-fourth of one redeemable warrant of